Mirum Pharmaceuticals Inc

Stage 2 advancing regime underpinned by an active Parabola pattern confirms a medium-term bullish bias. However, price is extended well above rising EMAs with extreme RSI and Options Score readings, making short-term timing unfavorable. We defer execution and will stalk for a pullback into the 9EMA/21EMA support zone.

• ↑Q1 net product sales reached $160M (+43% YoY); full-year outlook raised to $660–680M.
• ↑PROGRESS trial data on Zolurgocertib showed strong FOP efficacy, enhancing approval prospects.
• ↓Deeply negative earnings yield and low book-to-price ratio highlight valuation risk.